The report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.
This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
For more information about this report at http://www.reportsweb.com/myelodysplastic-syndrome-pipeline-review-h1-2016
- The report provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome
- The report reviews pipeline therapeutics for Myelodysplastic Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myelodysplastic Syndrome therapeutics and enlists all their major and minor projects
- The report assesses Myelodysplastic Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001276453/sample
Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myelodysplastic Syndrome
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myelodysplastic Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Companies profiles
Acceleron Pharma, Inc.
Actinium Pharmaceuticals, Inc.
Aeglea BioTherapeutics, Inc.
Agios Pharmaceuticals, Inc.
Altor BioScience Corporation
Arno Therapeutics, Inc.
Arog Pharmaceuticals, Inc.
Array BioPharma Inc.
Astex Pharmaceuticals, Inc.
Atara Biotherapeutics, Inc.
Bellicum Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
Boehringer Ingelheim GmbH
Boryung Pharmaceutical Co., Ltd.
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
Cantex Pharmaceuticals, Inc.
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001276453/discount
Few Points from List of Tables
Myelodysplastic Syndrome – Pipeline by Boryung Pharmaceutical Co., Ltd., H1 2016 66
Myelodysplastic Syndrome – Pipeline by Boston Biomedical, Inc., H1 2016 67
Myelodysplastic Syndrome – Pipeline by Bristol-Myers Squibb Company, H1 2016 68
Myelodysplastic Syndrome – Pipeline by Cantex Pharmaceuticals, Inc., H1 2016 69
Myelodysplastic Syndrome – Pipeline by Celator Pharmaceuticals, Inc., H1 2016 70
Myelodysplastic Syndrome – Pipeline by Celgene Corporation, H1 2016 71
Myelodysplastic Syndrome – Pipeline by Celldex Therapeutics, Inc., H1 2016 72
Myelodysplastic Syndrome – Pipeline by Cellerant Therapeutics, Inc., H1 2016 73
Myelodysplastic Syndrome – Pipeline by Celyad SA, H1 2016 74
Myelodysplastic Syndrome – Pipeline by Constellation Pharmaceuticals, Inc., H1 2016 75
Myelodysplastic Syndrome – Pipeline by Cornerstone Pharmaceuticals, Inc., H1 2016 76
Myelodysplastic Syndrome – Pipeline by CrystalGenomics, Inc., H1 2016 77
Myelodysplastic Syndrome – Pipeline by CTI BioPharma Corp., H1 2016 78
Myelodysplastic Syndrome – Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 79
Myelodysplastic Syndrome – Pipeline by Daiichi Sankyo Company, Limited, H1 2016 80